BD delivered stronger-than-expected first-quarter performance, driven by disciplined execution, accelerated commercial initiatives, and broad-based growth across key end markets. The company reported total revenues of $5.252 billion, a 1.6% increase, and GAAP diluted EPS of $1.34. Adjusted diluted EPS was $2.91. The combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close today, marking a pivot to 'New BD' with a focus on commercial capabilities, innovation, and gross margin expansion.
Total revenues for the first quarter of fiscal 2026 reached $5.252 billion, an increase of 1.6% as reported and 0.4% on a foreign currency-neutral basis.
GAAP diluted EPS was $1.34, a 28.8% increase, while adjusted diluted EPS was $2.91, a decrease of 15.2%.
The company is completing the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, transitioning to 'New BD'.
BD affirmed its fiscal year 2026 revenue growth guidance and provided adjusted diluted EPS guidance for New BD, ranging from $12.35 to $12.65.
BD provided fiscal year 2026 guidance for 'New BD' following the separation of its Biosciences and Diagnostic Solutions business. The guidance reflects the expected performance of New BD only, with adjustments for corporate overhead migrating to Waters Corp., TSA income, and the benefit from the use of proceeds.
Analyze how earnings announcements historically affect stock price performance